DIA
Drug Information Association Logo

HOW DO PAYERS VIEW CURRENT DEVELOPMENTS IN THE HTA AND REGULATORY ENVIRONMENT?

Track:
HTA/Regulatory Interface

Day & Time:
March 26, 11:00AM - 12:30PM (Central European Standard Time)

Session Number:
0202

Room Number:
Room G

Type:
Session

Title:
HOW DO PAYERS VIEW CURRENT DEVELOPMENTS IN THE HTA AND REGULATORY ENVIRONMENT?

Chair(s):
Anna E. Bucsics, MD
Former Dept. Head, Dept. of Pharmaceutical Affairs, MAASSI
University of Vienna, Austria

Description:
A variety of collaborative efforts have been undertaken in recent years to support the interface between HTA bodies and regulators. How are these interfaces delivering to those that are responsible for paying for drugs and services? And, if Health Technology Assessments (HTAs) are carried out to support the decision-making process for payers, how useful are these assessments in reality and how are they used by payers when deciding whether or not to reimburse a product? Payers will be asked what they do with HTAs and how they include such assessments in their decision making.

Presentation(s) & Speaker(s):
G-BA’s Part in the Changing Situation of Payers in the HTA/Regulatory Environment
Antje Behring
Department of Pharmaceuticals
Federal Joint Committee (Gemeinsamer Bundesausschuss), Germany

EMA and NICE – How are their decisions viewed by a Clinical Commissioning Group?
Andrew Donald
Chief Officer
Stafford and Cannock Chase Clinical Commissioning Groups, United Kingdom

The Role of Payers in the HTA/Regulatory System - does the economic environment make a difference?
Judit Bidlo
Head of the Department of Medicines Reimbursement
National Health Insurance Fund, Hungary